Artificial intelligence is allowing chemists to find new way to synthesize drug molecules, and forcing drug developers to shore up their patent strategies.
There is a question that gets debated in congressional hearings, litigated in federal courts, and studied in academic journals with
943 drugs approved. $15M to $100M in development costs versus $2.6B for an NCE. One regulatory mechanism sits at the
505(b)(2) NDAs: The Complete IP, Litigation, and Commercial Strategy Guide for 2025 Read Post »
1. What Pharmaceutical Sales Data Actually Measures Pharmaceutical sales data is not a single dataset. It is a composite of
Drug Sales Data: The Complete Playbook for Channel Strategy and Portfolio Dominance Read Post »
How to use price erosion curves, Paragraph IV filings, Orange Book patent analysis, and biosimilar IP valuation to build a
Generic Entry Pricing: The Complete Drug Price Data Playbook for Portfolio Managers Read Post »
Generic drugs account for nearly 90% of all prescriptions dispensed in the United States yet represent only about 20% of
DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions Read Post »
Branded generics are generic drugs that have been given proprietary brand names. They have a small, but profitable place in the U.S. pharmaceutical market.
Branded Generics and Why They’re Profitable Read Post »
Pre-ANDA Litigation Strategy: The Complete Playbook for Building Unbreakable Drug Patent Portfolios For IP counsel, portfolio managers, R&D leads, and
Get fresh news and insights, drug patent expirations & more…
